Shinpoong Pharmaceutical신풍제약

Shinpoong Pharmaceutical is back to a thin operating profit on trailing numbers, but its shares have fallen sharply over the past year.

Shinpoong is a South Korean drugmaker with products including Medicutton, Hyal, Brefra, Ezero and the malaria treatment Piramax. Trailing results to H1 2026 show revenue of about ₩239B and an operating margin of 1.1%, but a net loss of about ₩0.8B, after heavy losses in 2021 to 2024. The stock closed at ₩8,670, down 32.9% over one year and well below its 52-week high of ₩15,900.

What stands out

• Trailing revenue is about ₩239.1B, up from ₩234.7B in 2025, while 2025 operating income was ₩14.3B (6.1% margin) before turning to a small operating profit of ₩2.7B (1.1%) on a trailing basis.
• Trailing net income is a loss of about ₩0.8B, so the company is roughly break-even at the operating line but not yet profitable after finance and other costs.
• Cash of about ₩48.1B exceeds borrowings of about ₩10.8B, and trailing free cash flow is about ₩13.6B; liabilities to equity is 31.8%.
• Price-to-book is 1.6 and price-to-sales is 1.9; P/E is not meaningful because earnings are negative on a trailing basis, and the company pays no dividend.
• Foreign ownership fell from 6.2% to 5.1% over 60 days, and foreign investors were net sellers over the last 20 days, while retail investors were net buyers.

What to watch

• Two 'major management matter relevant to investors' filings in September and October 2026 were listed, but the data does not say what they concern; check the original filings.
• The full-year 2026 results and next quarterly report are not in the data; the trailing net loss is the key figure to track.
• The data does not include analyst forecasts, a fair value estimate or recent news headlines, so the outlook for the business cannot be assessed from this pack.